Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma

British Journal of Cancer

Volumn 110, Issue 4, 2014, Pages 984-990

  Ghanim, B ^a,b   Hoda, M A ^a,b   Klikovits, T ^a   Winter, M P ^a   Alimohammadi, A ^a   Grusch, M ^b   Dome, B ^a,c,d   Arns, M ^e   Schenk, P ^e   Jakopovic, M ^f   Samarzija, M ^f   Brcic, L ^f   Filipits, M ^b   Laszlo, V ^a,g   Klepetko, W ^a   Berger, W ^b   Hegedus, B ^a,b,h  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^d NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^e University Hospital Center ^*  (Austria)

^f UNIVERSITY OF ZAGREB   (Croatia)

^g EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^h INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

COMBINED MODALITY THERAPY; FEMALE; FIBRINOGEN; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84894307206     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.815     Document Type: Article

References (23)

1. Cao C, Yan TD, Bannon PG, McCaughan BC (2011) Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol 18(10): 2973-2979.
2. Clauss A (1957) [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol 17(4): 237-246.
3. Du J, Zheng JH, Chen XS, Yang Q, Zhang YH, Zhou L, Yao X (2013) High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis in renal cell carcinoma. Int J Clin Oncol 18(3): 517-523.
4. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, Lomas DA (2013) Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 68(7): 670-676.
5. Ghanim B, Hoda MA, Winter MP, Klikovits T, Alimohammadi A, Hegedus B, Dome B, Grusch M, Arns M, Schenk P, Pohl W, Zielinski C, Filipits M, Klepetko W, Berger W (2012) Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: A retrospective multicenter analysis. Ann Surg 256(2): 357-362.
6. Gulen ST, Karadag F, Karul AB, Kilicarslan N, Ceylan E, Kuman NK, Cildag O (2012) Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung 190(3): 327-332.
7. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27(18): 3007-3013.
8. Laurens N, Koolwijk P, de Maat MP (2006) Fibrin structure and wound healing. J Thromb Haemost 4(5): 932-939.
9. Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, Ninomiya K, Higashino K (1998) Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 77(6): 907-912.
10. Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, Williams SA, Levin S, Black B, Harbut M, Carbone M, Goparaju C, Pass HI (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One 7(10): E46091.
11. Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L (2009) Plasma fibrinogen levels and prognosis in patients with ovarian cancer: A multicenter study. Oncologist 14(10): 979-985.
12. Qiu J, Yu Y, Fu Y, Ye F, Xie X, Lu W (2012) Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 38(4): 651-657.
13. Rosenson RS, Koenig W (2003) Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 92(1A): 10i-18ii.
14. Rusch VW (1996) A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14(1): 1-12.
15. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Pechoux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35(3): 479-495.
16. Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L (2010) The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: A multi-centre trial. Br J Cancer 102(6): 952-956.
17. Seebacher V, Polterauer S, Grimm C, Tempfer C, Hefler-Frischmuth K, Reinthaller A, Hefler L (2012) The impact of plasma fibrinogen levels on patients with vulvar cancer. Eur J Obstet Gynecol Reprod Biol 161(1): 88-91.
18. Son HJ, Park JW, Chang HJ, Kim DY, Kim BC, Kim SY, Park SC, Choi HS, Oh JH (2013) Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol 20(9): 2908-2913.
19. Stahel RA, Weder W, Lievens Y, Felip E (2010) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): V126-v128.
20. Tanaka N, Kikuchi E, Matsumoto K, Hayakawa N, Ide H, Miyajima A, Nakamura S, Oya M (2012) Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma. BJU Int 111(6): 857-864.
21. Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J (2010) High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol 102(5): 428-432.
22. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O'Brien M, Thomas G, Senan S, O'Byrne K, Kilburn LS, Spicer J, Landau D, Edwards J, Coombes G, Darlison L, Peto J (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12(8): 763-772.
23. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14): 2636-2644.